Daiichi Sankyo is eliminating approximately 280 U.S. jobs in a restructuring it said will better align its U.S. commercial operations with its current portfolio of marketed drugs and pipeline of cancer treatments. The 280 to be laid off are based at various locations in the U.S. The company bases its U.S. corporate headquarters in Basking Ridge, N.J., with two Daiichi Sankyo-owned companies also based stateside—Luitpold Pharmaceuticals, a Shirley, NY, manufacturer and marketer of pharmaceuticals for animals, and Plexxikon, a Berkeley, CA, company focused on research of prescription drugs. “While the decision to reduce our workforce is a very difficult one, the changes are necessary to position us for long-term success,” Ken Keller, president, administrative and commercial, Daiichi Sankyo, said in a statement yesterday. “Our priorities are to bring spending in line with revenue, shift resources to maximize Injectafer ® and our abuse-deterrent pain treatments, and prepare for ...
Original Article: Daiichi Sankyo Eliminates 280 U.S. Jobs